Drug Discovery Services
Aurora is a drug discovery company and it offers the drug development services based on cheminformatics - computer aided drug design (structure based drug design or in silico drug designing) including docking molecular, drug target identification, drug discovery screening - small molecule screening, library screening, ion channel screening - fragment based drug design, ligand based drug design, ligand protein binding, protein ligand docking calculation and prediction, drug profiling, lead identification, lead compound identification and lead optimization.
Most of compound designs, chemistry library, screening library, and testing compounds are made at Aurora's own facilities in the US and in Austria, some of medicinal chemistry as potential drug discovery outsourcing might be performed by our subcontractors in North America and Europe.
Almost a thousand biotech companies in the USA are pursuing anticancer drug discovery projects, of which over half are concentrated on cancer drug development and cancer treatment. Aurora is offering the researchers drug-like lead compounds, chemical compound libraries including screening compounds: small molecules, natural compounds as well as diversity libraries, custom libraries, e.g. angiogenesis inhibitors, gpcr library, kinase library, kinase inhibitor library.
Aurora's rational drug design helps the scientists in both their conventional anticancer drug development efforts on tumor regression and a new drug discovery process of identification the new agents and their evaluation as drug candidates.
An important element of Aurora's antibacterial drug discovery service is in silico drug design of molecularly targeted fine chemicals, small molecule drugs, screening compounds, common compound library, diverse chemical compound library, fragment compound library, screening libraries.
Aurora Fine Chemicals offers the following drug discovery services that will benefit your projects:
- Virtual screening
- Chemical and physiological properties prediction